Literature DB >> 16236900

Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Hassan F Nadrous1, Patricia A Pellikka, Michael J Krowka, Karen L Swanson, Nithima Chaowalit, Paul A Decker, Jay H Ryu.   

Abstract

STUDY
OBJECTIVES: To determine the impact on survival and clinical correlates of pulmonary hypertension (PH) occurring in patients with idiopathic pulmonary fibrosis (IPF).
DESIGN: Retrospective study.
SETTING: Tertiary care, referral medical center. PATIENTS: Among 487 consecutive patients with IPF, we identified 136 patients who underwent transthoracic echocardiography within 3 months of their initial evaluation at our institution. Patients with left ventricular dysfunction, valvular heart disease, incomplete follow-up, and those in whom pulmonary artery pressures could not be assessed were excluded; the remaining 88 patients were included in this study. Correlations were performed between echocardiographic measures of PH and clinical variables including survival. MEASUREMENTS AND
RESULTS: The mean (+/- SD) estimated systolic pulmonary artery pressure (SPAP) for the 88 patients was 48 +/- 16 mm Hg (range, 28 to 116 mm Hg). Among pulmonary function parameters, SPAP correlated best with diffusing capacity of the lung for carbon monoxide (D(LCO)), to which it was inversely related. For survival analysis, patients were stratified into three groups: < or = 35 mm Hg (14 patients), 36 to 50 mm Hg (47 patients), and > 50 mm Hg (27 patients). Using the Kaplan-Meier method, the median survival rates for these three groups were 4.8 years, 4.1 years, and 0.7 years, respectively. Those patients with SPAP > 50 mm Hg had significantly worse survival compared to other subgroups (p = 0.009).
CONCLUSION: In patients with IPF, PH correlates inversely with D(LCO) and has a significant adverse impact on survival, particularly when SPAP is > 50 mm Hg.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236900     DOI: 10.1378/chest.128.4.2393

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  90 in total

1.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

Review 2.  Fibrogenesis: Mechanisms, Dynamics and Clinical Implications.

Authors:  Mark Daniel Wilson
Journal:  Iran J Pathol       Date:  2015

3.  Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis.

Authors:  D J Lederer; S M Arcasoy; R G Barr; J S Wilt; E Bagiella; F D'Ovidio; J R Sonett; S M Kawut
Journal:  Am J Transplant       Date:  2006-07-26       Impact factor: 8.086

Review 4.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

5.  Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  David A Zisman; David J Ross; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Arun S Karlamangla
Journal:  Respir Med       Date:  2007-07-02       Impact factor: 3.415

6.  Interstitial lung disease in a child with antisynthetase syndrome.

Authors:  Don Hayes; Peter B Baker; Heidi M Mansour; Mark E Peeples; Kathleen K Nicol
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

7.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

8.  High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Arun S Karlamangla; David J Ross; Michael P Keane; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Jonathan Goldin
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

Review 9.  Cardiac manifestations of idiopathic pulmonary fibrosis.

Authors:  Abhinav Agrawal; Isha Verma; Varun Shah; Abhishek Agarwal; Rutuja R Sikachi
Journal:  Intractable Rare Dis Res       Date:  2016-05

Review 10.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.